165 related articles for article (PubMed ID: 20357430)
1. C-peptide as a therapeutic tool in diabetic nephropathy.
Hills CE; Brunskill NJ; Squires PE
Am J Nephrol; 2010; 31(5):389-97. PubMed ID: 20357430
[TBL] [Abstract][Full Text] [Related]
2. Biological Activity of c-Peptide in Microvascular Complications of Type 1 Diabetes-Time for Translational Studies or Back to the Basics?
Ryk A; Łosiewicz A; Michalak A; Fendler W
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419247
[TBL] [Abstract][Full Text] [Related]
3. [Physiological effects of C-peptide].
Tsimaratos M
Nephrologie; 2004; 25(5):155-61. PubMed ID: 15455788
[TBL] [Abstract][Full Text] [Related]
4. Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide.
Sima AA
J Neurol Sci; 2004 May; 220(1-2):133-6. PubMed ID: 15140622
[No Abstract] [Full Text] [Related]
5. The effect of C-peptide on diabetic nephropathy: A review of molecular mechanisms.
Yaribeygi H; Maleki M; Sathyapalan T; Sahebkar A
Life Sci; 2019 Nov; 237():116950. PubMed ID: 31605709
[TBL] [Abstract][Full Text] [Related]
6. C-peptide and diabetic kidney disease.
Brunskill NJ
J Intern Med; 2017 Jan; 281(1):41-51. PubMed ID: 27640884
[TBL] [Abstract][Full Text] [Related]
7. Intracellular signalling by C-peptide.
Hills CE; Brunskill NJ
Exp Diabetes Res; 2008; 2008():635158. PubMed ID: 18382618
[TBL] [Abstract][Full Text] [Related]
8. Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy.
Opazo-Ríos L; Plaza A; Sánchez Matus Y; Bernal S; Lopez-Sanz L; Jimenez-Castilla L; Carpio D; Droguett A; Mezzano S; Egido J; Gomez-Guerrero C
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545818
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of C-peptide on experimentally induced diabetic nephropathy and the possible link between C-peptide and nitric oxide.
Elbassuoni EA; Aziz NM; El-Tahawy NF
Appl Physiol Nutr Metab; 2018 Jun; 43(6):617-624. PubMed ID: 29351386
[TBL] [Abstract][Full Text] [Related]
10. C-Peptide effects on renal physiology and diabetes.
Rebsomen L; Khammar A; Raccah D; Tsimaratos M
Exp Diabetes Res; 2008; 2008():281536. PubMed ID: 18509500
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism.
Liang G; Song L; Chen Z; Qian Y; Xie J; Zhao L; Lin Q; Zhu G; Tan Y; Li X; Mohammadi M; Huang Z
Kidney Int; 2018 Jan; 93(1):95-109. PubMed ID: 28750927
[TBL] [Abstract][Full Text] [Related]
12. C-peptide: a new potential in the treatment of diabetic nephropathy.
Wahren J; Ekberg K; Samnegård B; Johansson BL
Curr Diab Rep; 2001 Dec; 1(3):261-6. PubMed ID: 12643208
[TBL] [Abstract][Full Text] [Related]
13. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway.
Ji X; Li C; Ou Y; Li N; Yuan K; Yang G; Chen X; Yang Z; Liu B; Cheung WW; Wang L; Huang R; Lan T
Mol Cell Endocrinol; 2016 Dec; 437():268-279. PubMed ID: 27378149
[TBL] [Abstract][Full Text] [Related]
14. C-peptide ameliorates renal injury in type 2 diabetic rats through protein kinase A-mediated inhibition of fibronectin synthesis.
Xu S; Jiang Y; Wang H; Wang Z; Liu H; Peng L; Fang Q; Deng T; You J; Zhou X; Zhang W; Lou J
Biochem Biophys Res Commun; 2015 Mar; 458(3):674-680. PubMed ID: 25684188
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
[TBL] [Abstract][Full Text] [Related]
16. C-peptide, Na+,K(+)-ATPase, and diabetes.
Vague P; Coste TC; Jannot MF; Raccah D; Tsimaratos M
Exp Diabesity Res; 2004; 5(1):37-50. PubMed ID: 15198370
[TBL] [Abstract][Full Text] [Related]
17. C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells.
Zhong Z; Davidescu A; Ehrén I; Ekberg K; Jörnvall H; Wahren J; Chibalin AV
Diabetologia; 2005 Jan; 48(1):187-97. PubMed ID: 15624099
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-κB pathway.
Wang H; Huang X; Xu P; Liu X; Zhou Z; Wang F; Li J; Wang Y; Xian X; Liu G; Huang W
Metabolism; 2021 Jun; 119():154740. PubMed ID: 33639183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
